These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12127620)

  • 1. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation.
    Gurbel PA; Malinin AI; Callahan KP; Serebruany VL; O'Connor CM
    Am J Cardiol; 2002 Aug; 90(3):312-5. PubMed ID: 12127620
    [No Abstract]   [Full Text] [Related]  

  • 2. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
    Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting.
    Antonino MJ; Mahla E; Bliden KP; Tantry US; Gurbel PA
    Am J Cardiol; 2009 Jun; 103(11):1546-50. PubMed ID: 19463513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Platelet aggregation upon acetylsalicylic acid and clopidogrel treatment and glycoprotein IIb/IIIa content in patients with acute coronary syndrome].
    Khaspekova SG; Ziuriaev IT; Iakushkin VV; Golubeva NV; Ruda MIa; Mazurov AV
    Kardiologiia; 2011; 51(7):4-7. PubMed ID: 21878077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet function in clopidogrel-treated patients with acute coronary syndrome.
    Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):335-9. PubMed ID: 17473574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation.
    Sacristán D; López-Farré AJ; Zamorano-León JJ; Azcona L; Fernández-Ortiz A; Romero J; Farré J; Macaya C
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):286-92. PubMed ID: 18356694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
    Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
    Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.
    Bliden KP; Dichiara J; Lawal L; Singla A; Antonino MJ; Baker BA; Bailey WL; Tantry US; Gurbel PA
    J Am Coll Cardiol; 2008 Aug; 52(7):531-3. PubMed ID: 18687246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
    Gremmel T; Eslam RB; Koppensteiner R; Lang IM; Panzer S
    Cardiovasc Ther; 2013 Oct; 31(5):e40-5. PubMed ID: 23311679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model.
    Klinkhardt U; Graff J; Harder S
    Clin Pharmacol Ther; 2002 Mar; 71(3):176-85. PubMed ID: 11907492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
    Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
    Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study.
    Gurbel PA; Bliden KP; Tantry US
    J Am Coll Cardiol; 2006 Dec; 48(11):2186-91. PubMed ID: 17161243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
    J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis.
    Gurbel PA; Samara WM; Bliden KP
    Platelets; 2004 Mar; 15(2):95-9. PubMed ID: 15154601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.